Segment
Type of investment
Commercial Growth
The commercial growth segment consists of companies that are already selling products or services and showcasing proof-of-concept with high growth and potential to reach profitability in the near term. These companies are generally derisked in terms of technical and product development risks, but often require larger investments and generate lower multiples.
Flerie supports expansion through organic growth and M&A opportunities. Flerie will retain the investment as long as it creates value.
Nanologica
Nanologica is a publicly listed Swedish nanotechnology company developing nanoporous silica particles for preparative chromatography, a type of purification technique. The company’s silica media NLAB Saga® can reduce the production cost for drug manufacturers significantly, given its optimised combination of pore volume and high available surface area, in addition to its exceptional mechanical and chemical stability. This ultimately decreases the number of purification cycles needed in the manufacturing process in addition to decreasing total silica consumption. It is ideal for the purification of peptides such as insulin, insulin analogues and GLP-1 analogues (a rapidly growing new drug class). The company has a production facility in the United Kingdom and has recently received several orders for NLAB Saga® from major customers in Asia, the US, and Latin-America.
Sweden
Andreas Bhagwani
Limited partnerships
Under certain circumstances, Flerie will become a limited partner in a fund. This allows Flerie to access the network, opportunities and skills of another investment company. This segment provides benefits for the other two segments, including co-investment opportunities, and derisks Flerie’s investment portfolio. The segment also enables further diversification and sourcing potential.
Undisclosed fund 1
Focused on life science companies
Undisclosed fund 2
Focused on life science companies
Undisclosed fund 3
Focused on sustainable technology companies